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N-linked glycosites database <p>UniPep, a database of human N-linked glycosites is presented as a resource for biomarker discovery</p>
Abstract
There has been considerable recent interest in proteomic analyses of plasma for the purpose of
discovering biomarkers. Profiling N-linked glycopeptides is a particularly promising method because
the population of N-linked glycosites represents the proteomes of plasma, the cell surface, and
secreted proteins at very low redundancy and provides a compelling link between the tissue and
plasma proteomes. Here, we describe UniPep http://www.unipep.org - a database of human N-
linked glycosites - as a resource for biomarker discovery.
Rationale
It is generally understood that variations in an individual's
genetic background and physiologic state give rise to altera-
tions in the person's plasma protein profile. (For the purposes
of this report, the terms 'serum' and 'plasma' are used inter-
changeably.) Of particular interest are those changes that
reflect important processes in specific organs or tissues, such
as the early onset of pathologic processes or the response to
pharmacologic intervention. The detection and correct inter-
pretation of the respective plasma proteome patterns are
expected to realize a significant benefit for human health
through the development of simple blood tests for (early)
detection and stratification of many of the common serious
human diseases (for example, cancers, neurodegenerative
disorders, and diabetes, among others). The great potential
impact of the information contained in the plasma proteome
has resulted in a strong focus of applying a range of proteomic
strategies to discover and detect relevant plasma proteome
markers or patterns [1-7].
Several factors complicate plasma proteomic analyses in gen-
eral and specifically the detection of proteins in plasma that
are derived from a particular tissue. Complications include
the enormous complexity of the plasma proteome, the high
dynamic range of protein concentrations, the dominance of
the plasma proteome by few highly expressed proteins, and
the expected substantial dilution of tissue-derived proteins in
the large pool of an individual's blood [8]. In addition, it
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appears that the plasma protein composition varies substan-
tially between individuals in a population [9] and within an
individual as a function of a multitude of factors, including
sex, age, general health, and external and lifestyle influences
[10,11]. Partly as a result of these complications, attempts to
discover sensitive and selective biomarkers using the availa-
ble proteomic strategies, including two-dimensional gel elec-
trophoresis [3], shotgun tandem mass spectrometry (MS/
MS) [1,2,7,12,13], surface-enhanced laser/desorption ioniza-
tion (SELDI)-MS [14], and others, have met with modest suc-
cess. In fact, at this point not a single validated biomarker has
been identified using these proteomic methods. Careful anal-
ysis of the results produced by such studies has indicated the
restricted dynamic range of the analytical methods used as a
main limitation [15]. Each one of the methods has demon-
strated ability to reliably detect and identify quantitative
changes in proteins in the top two to four orders of magnitude
of the dynamic range of the plasma proteome, which is
thought to span minimally 10 orders of magnitude. Therefore,
current methods are largely blind to the majority of plasma
proteins, especially to those that are released by specific tis-
sues at low concentrations.
The current most promising strategy to overcome these limi-
tations is to fractionate the plasma proteome into minimally
overlapping fractions and to analyze by MS each fraction sep-
arately. In addition to fractionation schemata based on phys-
icochemical properties of proteins and peptides such as size,
charge, and hydropathicity, the specific selection of subpro-
teomes that contain a particular functional group and the
depletion of plasma for highly expressed proteins have been
successfully applied [16].
Our group introduced a method for the selective isolation of
N-linked glycopeptides, and analysis of the complex peptide
mixture representing the now de-glycosylated forms of these
peptides by MS/MS [17]. This method further enables high-
throughput identification of N-linked glycosylation sites (N-
linked glycosites), defined as the acceptor asparagines for N-
linked glycosylation to take place on protein sequences. By
selectively isolating this subset of peptides, the procedure
achieves a significant reduction in analyte complexity at two
levels. First, it reduces the total number of peptides because
of the fact that every plasma protein on average only contains
a few N-linked glycosites. Second, it reduces pattern complex-
ity by removing the oligosaccharides that contribute signifi-
cantly to the peptide pattern heterogeneity. We have shown
that application of the method to plasma results in a signifi-
cant reduction in sample complexity, increased sample
throughput, and increased dynamic range for proteome anal-
ysis [17,18]. However, the most significant benefits from the
selective analysis of N-linked glycopeptides originate from
the fact that the number of N-linked glycosites in the human
proteome is modest, known in principle, and identifiable with
current technology.
This situation has profound conceptual and experimental
implications for biomarker discovery. First, biomarker dis-
covery research using this approach operates in a defined
space; all of the biomarkers discovered by the method for any
disease will be a subset of the known N-linked glycosites. The
benefits of navigating in a mapped space as opposed to de
novo discovery of the observable events in each experiment
have been impressively demonstrated by the genomic sci-
ences. Second, the data units generated by the method are
specific N-linked glycosites; therefore comparison between
studies, labs and disease types is significantly simplified. It
will, for instance, become trivial to compare a biomarker data
set for a particular disease with the one generated for differ-
ent diseases to determine whether the putative marker is dis-
ease specific or a pan-disease marker. Third, the relatively
modest number of possible N-linked glycosites will facilitate
the development of targeted approaches for high-throughput
proteomic screening, for instance via screening ordered pep-
tide arrays by matrix-assisted laser desorption/ionization
(MALDI)-MS/MS [19,20]. Finally, the same pool of N-linked
glycosites can be explored to generate potential marker pat-
terns from the cell surface and secreted protein populations
of cells and tissues, and for the targeted search for such tis-
sue-derived patterns in plasma, thus dramatically reducing
the challenge of defining biomarker patterns from global
plasma protein profiles. It is therefore apparent that knowl-
edge of all N-linked glycosites of the human proteome and
their organization in a relational database would be of signif-
icant interest for protein biomarker discovery.
In this report we describe UniPep, which is a database for
human N-linked glycosites that can be interrogated via the
internet [21]; the informatics infrastructure to populate the
database with data of consistent quality; and an initial set of
1522 unique N-linked glycosites identified at high confidence,
representing an estimated 3% of the total number of N-linked
glycosites of the human proteome and 7% of the N-linked gly-
cosites from proteins predicted as being secreted or trans-
membrane proteins.
Results and discussion
UniPep: a database for human N-linked glycosites
N-linked glycosites generally fall into the N-X-S/T sequence
motif, in which X denotes any amino acid except proline [22].
The number and distribution of the N-linked glycosites over
the human proteome can therefore be computationally deter-
mined by scanning the sequences for the presence of the
motif. To display all the theoretical N-linked glycosites in the
human International Protein Index (IPI) database (version
2.28) and to relate them to the N-linked glycosites that were
experimentally observed by mass spectrometric analysis, we
developed the UniPep database and web interface [21]. The
potential N-linked glycosites were parsed and loaded into a
relational database and the data are easily searchable using
SQL (structured query language). User access to the databasehttp://genomebiology.com/2006/7/8/R73 Genome Biology 2006,     Volume 7, Issue 8, Article R73       Zhang et al. R73.3
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is provided via a cgi web interface, which is part of the larger
application framework named Systems Biology Experiment
Analysis Management System relational database (SBEAMS
[23]).
The primary user interface is a search page that allows users
to search the data based on various parameters and supports
the use of wild card characters. Possible search parameters
include amino acid sequence, gene symbol, gene name,
Swiss-Prot accession number, or IPI accession number.
When a search is executed a list of all proteins that match the
search criteria is shown. Each listing contains a link to view a
detailed record for the respective protein.
For each protein in the UniPep database, we display four dif-
ferent types of information (Figure 1). The first section, Pro-
tein Info, indicates the predicted subcellular location of the
protein along with other information about the respective
protein from Entrez Gene [24]. N-linked glycosylation is
enriched in proteins destined for extracellular environments
[25]. These include proteins on the extracellular side of the
plasma membrane (cell surface proteins), transmembrane
proteins, and secreted proteins. We predicted the subcellular
localization of each protein based on whether a protein con-
tains a signal peptide (computed using the program SignalP
2.0 [26]) and/or transmembrane region(s) (computed using
the program TMHMM [version 2.0] [27]). The proteins were
thus categorized as cell surface, secreted, transmembrane, or
intracellular.
In the second section, Predicted N-linked Glycopeptides, the
sequences of potential tryptic N-linked glycosites and their
location within the protein sequence are displayed. Some
potential N-linked glycopeptides (7.9% of unique N-linked
glycopeptides) contain multiple N-X-S/T sites within a pre-
dicted tryptic peptide; in this case, each N-X-S/T site was
considered an N-linked glycosite. We also determined the
uniqueness of each predicted N-linked glycosite by searching
the entire IPI protein database for the number of occurrences
of the respective sequence in different proteins. The results of
these analyses are annotated under 'number of proteins with
peptide' (Figure 1).
In the third section, Identified N-linked Glycopeptides, the
mass spectrometrically identified peptides along with rele-
vant annotations are displayed. For the identified N-linked
glycosites, sequences from SEQUEST search result were
mapped to the potential N-linked glycosites from the IPI
database and the overlapping sequences containing the same
N-linked glycosites were resolved to generate nonredundant
N-linked glycopeptide (see rules below). For the protein in
Figure 1 all of the predicted N-linked glycosites were indeed
observed, although the site at position 249 was observed as a
peptide with a missed tryptic cleavage site immediately pre-
ceding the site of carbohydrate attachment.
In the fourth section, Protein/Peptide Sequence, the whole
protein sequence is indicated and the signal peptides, trans-
membrane sequences, and identified N-linked glycosites are
highlighted to give a general indication of protein topology.
Table 1 details the number of predicted unique N-linked gly-
cosites in the human proteome and their distribution over the
cell surface, secreted, transmembrane, or intracellular frac-
tions. The table also indicates the degree of simplification
achieved by focusing on the N-linked glycosites compared
with analysis of the whole proteome, assuming occupancy of
each potential N-linked glycosite.
Without considering possible sequence variation and post-
translational modifications of each peptide, 749,163 unique
tryptic peptides within a mass range of 500-5000 are
expected from the protein entries in the IPI database. Of
these, 52,442 unique peptides (7.0%) contain potential N-
linked glycosites. These 7.0% N-X-T/S containing peptides
represent 67.5% of the proteins in the database. Furthermore,
only about 33.4% of proteins (13,389 protein entries) from
the human protein database are predicted to be exposed to an
extracellular environment and therefore are likely to be glyc-
osylated [28]. These predicted extracellular proteins contain
22,692 unique N-X-T/S motif containing peptides represent-
ing 3.0% of the total unique tryptic peptides. These 3.0% of
peptides represent 9583 protein entries (71.6% of 13,389 pro-
teins predicted as being extracellular proteins; Table 1). This
suggests that the number of N-linked glycosites in the human
proteome is modest (3.0% of total expected peptides), known
in principle, and identifiable with current technology. N-
linked glycopeptide analysis therefore targets a relatively
small fraction of peptides from complex human plasma pro-
teome that are enriched for the proteins exposed to extracel-
lular side of the plasma membrane. The modest number of
potential N-linked glycosites indicates that the selective isola-
tion of these peptides results in a substantial reduction in the
redundancy inherent in serum proteome analysis and that the
concentration limit of detection is therefore significantly
improved because of the reduction in sample complexity [18].
Analysis of N-linked glycosites reveals potential biomarkers
that change in glycoproteins and glycosite occupancy; this is
supported by the observation that most known clinical pro-
tein markers are also known to be glycosylated. The reduction
in sample complexity is beneficial for achieving higher sensi-
tivity for low abundance proteins, but it also leads to the loss
of some, potentially important information. Potential disease
markers that are due to changes in nonglycosylated proteins,
other protein post-translational modifications, and oligosac-
charide structures will not be detected at a glycopeptide level.
Informatics infrastructure for automatic and 
consistent data processing in UniPep
The utility of the UniPep database as a public resource
depends on the number of N-linked glycosites identified byR73.4 Genome Biology 2006,     Volume 7, Issue 8, Article R73       Zhang et al. http://genomebiology.com/2006/7/8/R73
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MS at high confidence. The limited number of N-linked gly-
cosites in the human proteome suggests that all or at least the
majority of these peptides can be identified if respective data
from different experiments and laboratories are integrated
into a single comprehensive database. We therefore devel-
oped an informatics infrastructure for the identification of N-
linked glycosites from MS/MS spectra at consistent process,
irrespective of the origin of the raw data. The system builds on
SBEAMS [23] and the tools, procedures, and statistical mod-
els developed for the PeptideAtlas project [29-31] and the
Trans Proteomic Pipeline (TPP) [32].
The procedure to add new data to UniPep consists of the fol-
lowing five steps (Figure 2). In step 1, data submission, raw
MS/MS data from any type of tandem mass spectrometer can
be submitted and processed. The spectra are formatted, pref-
e r a b l y  i n t o  m z X M L  [ 3 3 ]  o r  mzData (HUPO Proteomics
Standards Initiative), which are open file formats for the rep-
resentation of MS data. Other data formats will be translated
into these formats and are therefore also acceptable.
In step 2, sequence assignment, the MS/MS data are searched
against a database (IPI version 2.28 for the current version of
Representative output of N-linked glycosites from database using UniPep Figure 1
Representative output of N-linked glycosites from database using UniPep. UniPep contains all proteins in the International Protein Index (IPI) database 
(version 2.28) with at least one N-linked glycosite and allows users to view all the predicted and identified N-linked glycosites from a specific protein. For 
each potential N-linked glycoprotein, a user can see the protein annotation, predicted subcellular location, and sequence(s) of predicted N-linked 
glycosites(s). The uniqueness of a peptide in the database is also presented as number of hits in the database, and for those peptides present in multiple 
proteins, linkage to other proteins in the database is provided. If any predicted N-linked glycosite was identified in the dataset from this study, then it is 
listed as an identified peptide with PeptideProphet score [39] to allow researchers to evaluate the confidence of the identification. The sequence of the 
proteins queried is overlaid with different sequence features such as the N-linked glycosites, the predicted and identified peptide sequences, signal peptide, 
and transmembrane segment(s) [21].http://genomebiology.com/2006/7/8/R73 Genome Biology 2006,     Volume 7, Issue 8, Article R73       Zhang et al. R73.5
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UniPep) by SEQUEST to correlate MS/MS spectra with the
amino acid sequences of the peptides. Other database search
engines, such as COMET [32], MASCOT [34], and ProbID
[35], can also be used because they are supported by current
TPP [32] and UniPep. Support for several other search
engines, such as X!Tandem [36], PHENYX [37], and OMSSA
[38] is planned in subsequent TPP releases, and would thus
be supported by UniPep.
Statistical analysis, step 3, involves further analysis of
assigned peptide sequences using PeptideProphet [39]. Based
on the distribution of scores over the whole dataset, Peptide-
Prophet calculates for each peptide a probability of the
assignment being correct. The information used by Peptide-
Prophet includes database search scores, difference between
the measured and theoretical peptide mass, the number of
termini consistent with the type of enzymatic cleavage used,
the number of missed cleavage sites, and other factors. Pepti-
deProphet also calculates for each dataset false-positive and
false-negative error rates at specific probability score cutoff
values [40]. A minimum PeptideProphet probability score of
≥0.5 was initially used to remove low probability peptides.
Using a probability score of ≥0.5 as the cutoff, the estimated
false-positive and false-negative rates generally fall below
10% and 20%, respectively (Table 2). The identified peptide
sequences with their probability score and the corresponding
MS/MS spectra are output using INTERACT for inclusion in
the database [41].
In step 4, nonredundant N-linked glycopeptide generation,
peptides with overlapping sequences containing the same (for
example, redundant) N-X-S/T sequons from the same dataset
are resolved in favor of those sequences that contain the
greater number of tryptic ends, a lower number of miss-
cleaved internal tryptic sites, and higher PeptideProphet
probability. The fifth and final step is N-linked glycosite map-
ping to protein database. The peptide sequences from the
nonredundant list constitute sequence patterns that are used
to match each peptide against the corresponding N-linked
glycosite in the IPI database. This step results in a set of IPI
numbers with the location of each specific N-X-T/S site to
which the given peptide will match. These locations are con-
catenated into a unique key (for instance, IPI00000001 site
327 becomes IPI00000001.327), and occurrence of the
matching peptide object is mapped to each key within N-
linked glycosites in UniPep. If a peptide has already been
mapped to a particular IPI.N-X-T/S key, then the new and
existing peptides are merged (as described in step 4,
described above) and the better peptide is chosen.
This procedure ensures the highest degree of consistency for
data in UniPep. All MS/MS spectra are stored and available in
the mzXML files in the SBEAMS - Proteomics database [23],
from which UniPep is derived. Thus, collectively, the steps in
this procedure produce a database, UniPep, that contains a
minimal set of peptides containing the consensus N-linked
glycosylation motif, the MS/MS spectra representing the pep-
tide, and the likelihood that the peptide has been correctly
identified (Figure 1).
Only peptides containing consensus N-linked glycosites (the
N-X-T/S motif) are used to predict the potential N-linked gly-
cosites from protein sequences in the database, and only the
identified peptides containing the N-linked glycosites are
used to map to the potential N-linked glycosites. Peptides not
containing the sequon can come from three sources. The first
is from peptides resulting from nonspecific isolation in the
glycopeptide isolation procedure, the second from incorrect
peptide sequence assignments (false positives), and the third
from atypical N-linked glycosylation in which glycosylation
occurs in sequences other than the consensus N-X-S/T motif
such as N-X-C motif [42]. Currently, we exclude atypical N-
linked glycopeptides in UniPep database because of lack of
understanding of consensus atypical sequence motifs. Pep-
tides not containing N-X-S/T motif were stored in PeptideAt-
las [29,43], and peptide identification information including
Table 1
Distribution of unique tryptic peptides and tryptic peptides containing the N-X-T/S motif over subcellular classes of proteins in the 
human protein (IPI) database
Tryptic peptidesa Peptides containing N-X-T/S
Number of peptidesa Number of proteins Number of peptidesa Number of proteins
Intracellular 510,685(68.2%b) 26,721(66.6%c) 32,770(4.4%b) 17,475(43.6%c)
Secreted 80,069(10.7%) 3,772(9.4%) 7,195(1.0%b) 2,772(6.9%c)
Transmembrane 114,282(15.3%) 6,375(15.9%) 10,359(1.4%) 4,645(11.6%)
Cell surface 70,126(9.4%) 3,242(8.1%) 5,138(0.7%) 2,166(5.4%)
All extracellular 264,477(35.5%) 13,389(33.4%) 22,692(3.0%) 9,583(23.9%)
Total protein 749,163(100%) 40,110(100%) 52,442(7.0%) 27,058(67.5%)
The human International Protein Index (IPI) database (version 2.28) contains a total of 40,110 protein entries. aTryptic peptides are defined as 
peptide sequences that end with Arg or Lys, are not followed by proline, and fall within the mass range from 500 to 5000 Da. bThe percentage 
represents the fraction of total tryptic peptides from the human database (749,163). cThe percentage represents the fraction of total proteins from 
the human database (40,110).R73.6 Genome Biology 2006,     Volume 7, Issue 8, Article R73       Zhang et al. http://genomebiology.com/2006/7/8/R73
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sequence, PeptideProphet, and number of times each
sequence was identified was recorded and displayed in
PeptideAtlas. A link to PeptideAtlas is provided for each iden-
tified peptide and protein in the column entitled 'Atlas'. This
provides a number of links to other resources, such as
ENSEMBLE, via PeptideAtlas (Figure 1).
It is understood that nearly all large-scale datasets obtained
using high-throughput methods contain a certain fraction of
false-positive data. Thus, estimation of false-positive error
rates is a very important but often challenging task, particu-
larly in cases in which data from different datasets are merged
into a single database. The false-positive glycosites can be
grouped into two sources. The first source is the data acquisi-
tion including isolation of nonspecific glycopeptides and
analyses of the extracted peptides by MS. The glycosites in
this group contain peptides that are correctly identified by
SEQUEST search. Because N-linked glycosylation occurs in
sequences containing the N-X-S/T motif, we filtered the iden-
tified peptides with this consensus glycosylation motif to
reduce the false-positive peptides. The second source of false-
positive glycosites is from peptides that are incorrectly iden-
tified by SEQEST search. In the present analysis, the false-
positive error rate from SEQUEST search was estimated by
the PeptideProphet statistical model. One significant advan-
tage of establishing the automated infrastructure in this work
is that computed peptide probabilities from PeptideProphet
allow estimation of the likelihood of correct identification of
each identified glycosite.
To assess the overall false-positive rate of identified N-linked
glycosites using a particular probability threshold on the
number of identified N-linked glycosites, we filtered the iden-
tified N-linked glycosites using PeptideProphet probability
thresholds P ≥ 0.5, 0.8, 0.9, 0.95 and 0.99. Because protein
glycosylation, in particular N-linked glycosylation, occurs in
proteins destined for extracellular environments [25], we also
calculated the fraction of N-linked glycosites that are derived
from proteins predicted as 'intracellular proteins' or 'extracel-
lular proteins'. Decreasing the probability threshold increases
the number of unique N-linked glycosites identified as well as
the false-positive rate estimated by the rate of incorrect
assignment of N-linked glycosites to intracellular proteins.
Table 3 indicates the number of unique N-linked glycosites
derived from intracellular and extracellular proteins (includ-
ing secreted proteins, cell surface proteins, and transmem-
brane proteins) as a function of the PeptideProphet
probability values. As expected, we observed that the percent-
age of unique N-linked glycosites derived from intracellular
proteins decreased while extracellular proteins increased
Consistent analysis pipeline Figure 2
Consistent analysis pipeline. Shown is a schematic presentation of 
consistent analysis pipeline for the identification of high-quality N-linked 
glycosites using glycopeptide capture and LC-MS/MS. LC, liquid 
chromatography; MS/MS, tandem mass spectrometry.
Plasma, tissues, or cells
Isolation of N-linked glycopeptides
Generation of LC/MS/MS
Data submission
Sequence assignment
Statistical analysis
N-glycosite mapping 
to protein database
Non-redundant N-linked 
glycopeptides generation
UniPep
Table 2
False-positive and false-negative rates of peptide identifications in 
liver tissue predicted by PeptideProphet at different probability 
thresholds
Probability score cutoff False-negative rate False-positive rate
0.99 0.6042 0.0025
0.95 0.4037 0.0099
0.90 0.3297 0.0172
0.80 0.2621 0.0304
0.70 0.2252 0.0437
0.60 0.1964 0.0593
0.50 0.1713 0.0787
0.40 0.1440 0.1091
0.30 0.1262 0.1364
0.20 0.1041 0.1877
0.10 0.0724 0.3010
0.00 0.0000 0.9295http://genomebiology.com/2006/7/8/R73 Genome Biology 2006,     Volume 7, Issue 8, Article R73       Zhang et al. R73.7
c
o
m
m
e
n
t
r
e
v
i
e
w
s
r
e
p
o
r
t
s
r
e
f
e
r
e
e
d
 
r
e
s
e
a
r
c
h
d
e
p
o
s
i
t
e
d
 
r
e
s
e
a
r
c
h
i
n
t
e
r
a
c
t
i
o
n
s
i
n
f
o
r
m
a
t
i
o
n
Genome Biology 2006, 7:R73
with increasing stringency of the identification criteria (Fig-
ure 3). At the highest peptide probability score of 0.99 from
SEQUEST search, 8% of the identified N-linked glycosites
were from intracellular proteins (Figure 3). For comparison,
of the 52,442 unique N-X-T/S motif containing potential N-
linked glycosites from human protein database, 32,770
unique N-X-T/S N-linked glycosites are predicted to come
from intracellular proteins, representing 62.5% of the total N-
X-T/S motif containing sites (Tables 1 and 3, and Figure 3).
This indicates that our glycopeptide capture method has sig-
nificantly enriched the extracellular proteins, and the fraction
of glycosites from intracellular proteins is a reasonable esti-
mation of the overall false-positive rate that can result from
peptide assignment from SEQUEST search, nonspecific glyc-
opeptide isolation, and peptide analysis using MS/MS.
The most stringent threshold of P  ≥ 0.99 produced 1522
unique  N-linked glycosites, of which 8% of N-linked gly-
cosites were assigned to proteins predicted as being intracel-
lular proteins. Because a 0.99 probability threshold has a very
low false-positive error rate (with <1% error rate for peptide
assignment), we assumed that at least some of the proteins
not annotated as 'extracellular proteins' might represent mis-
prediction in the protein subcellular localization. Indeed,
closer examination of the data showed that at least some of
the identified N-linked glycosites were from proteins that
were known to be extracellular proteins (carboxypeptidase N
83 kDa chain, and different isoforms of immunoglobulins)
but incorrectly annotated as intracellular proteins. Therefore,
the real error rate might be lower than the error rate esti-
mated from the percentage of intracellular proteins.
Using a probability score of P ≥ 0.99 as cutoff, UniPep is cur-
rently populated with 1522 identified N-linked glycosites. As
discussed above, because at this stringency a fraction of the
true positive glycosites are lost, we provide on the UniPep
website the option for users to browse the N-linked glycosites
generated at the lower P thresholds at the user's own judg-
ment (subject to P ≥ 0.5). Using probability thresholds with
lower false-negative rates will be useful in those instances in
which a larger number of potential target peptides needs to be
identified (Tables 2 and 3).
Experimental identification of N-linked glycosites
To determine which of the potential N-linked glycosites were
actually glycosylated and can be experimentally confirmed in
a variety of samples, we isolated and analyzed N-linked gly-
cosites from plasma, cerebrospinal fluid (CSF), and various
tissue and cell sources using solid-phase extraction and MS/
MS [17]. The resulting spectra were processed through the
Table 3
Number of unique N-linked glycosites and percentage of sites from intracellular or extracellular proteins using different peptide prob-
ability thresholds
Probability threshold Database
≥0.5 ≥0.8 ≥0.9 ≥0.95 ≥0.99
Number of unique N-linked glycosites 5202 2870 2265 1895 1522 52442
Number of unique N-linked glycosites from 
intracellular proteins
2207 817 363 264 124 32770
Number of unique N-linked glycosites from secreted 
proteins
1326 1086 1011 946 834 7195
Number of unique N-linked glycosites from 
transmembrane proteins
976 523 408 337 263 10359
Number of unique N-linked glycosites from cell 
surface proteins
633 444 383 348 301 5138
Number of unique N-linked glycosites from all 
extracellular proteins
2935 2053 1802 1631 1398 22692
Ratio of identified N-linked glycosites identified from proteins predicted as  intracellular proteins and extracellular proteins Figure 3
Ratio of identified N-linked glycosites identified from proteins predicted as 
intracellular proteins and extracellular proteins. The extracellular proteins 
include secreted proteins, cell surface proteins, and transmembrane 
proteins. The findings are expressed a function of probability stringency.
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informatics system described above and entered into UniPep.
Currently, the database contains data generated in three dif-
ferent laboratories.
The deglycosylated peptides isolated from whole plasma or
plasma depleted of six high abundance proteins using the
glycopeptide capture method [12,17] were separated by two-
dimensional (strong cation exchange chromatography [SCX]
followed by reverse phase) liquid chromatography (LC) and
analyzed by electrospray ionization (ESI)-MS/MS on LCQ or
LTQ ion trap, or quadrupole time-of-flight (qTOF) mass spec-
trometers. Collectively, these measurements identified 828
N-linked glycosites at a minimum probability threshold of
0.99 (Table 4).
Formerly  N-linked glycopeptides wer e  i s o l a t e d  f r o m  C S F
using the method developed by Zhang and coworkers [7]. The
deglycosylated peptides were divided into two halves. One
half was separated by a two-dimensional microcapillary high-
performance liquid chromatography (LC) system, which
integrated a SCX column with two alternating reverse phase
C18 columns, followed by analysis of each peptide with MS/
MS in an LCQ ion trap. The other half of the CSF sample was
separated using offline reverse phase chromatography and
spotted onto a stainless steel MALDI plate for a total of 576
spots per plate. In total, four MALDI plates were spotted and
analyzed by a 4700 Proteomic Analyzer (Applied Biosystems,
Foster City, CA, USA). A total of 407 unique N-linked gly-
cosites at a minimum probability threshold of 0.99 were iden-
tified from CSF including 113 unique N-linked glycosites that
were only identified in CSF (Table 4).
N-linked glycosites from cell and tissue extracts were isolated
and identified using essentially the same protocols as for
plasma proteins, except that for some cell lines (Jurkat,
Ramos) the cell surface was labeled with biotinylated
hydrazide on the intact cells to achieve high selectivity for cell
surface proteins (Wollscheid and coworkers, unpublished
data). In addition to the Ramos and Jurkat cells, SK-BR-3
breast cancer cells, LNCaP prostate cancer cells, primary
bladder and prostate cancer tissue, and a primary liver metas-
tasis of prostate cancer were processed by homogenizing tis-
sues or cells followed by solid phase extraction of
glycopeptides [17]. The data from each tissue or cell line are
summarized in Table 4 and the sequence of the peptides iden-
tified from the respective sources is contained in the UniPep
database.
After searching the human IPI sequence database with the
whole dataset and statistical filtering of the resulting search,
the results collectively identified 1522 unique N-linked gly-
cosites, maximally representing 1391 proteins at a Peptide-
Prophet score of ≥0.99 (Table 4); 447 proteins were identified
by at least one unique N-linked glycosite that represents just
a single protein in the database.
Table 4
Summary of N-linked glycosites identified from different sample sources with probability score at least 0.99
Sample source Number of unique glycosites Number of source-specific glycosites Number of spectra used for ID
All 1,522 173,841
Plasma 828 433 156,814
Bladder 145 3 1,121
Breast cancer cells 369 135 2,725
Liver 202 13 964
Lymphocytes 288 156 2,847
Prostate cancer cells 71 4 108
Prostate tissue 354 53 3,804
Cerebrospinal fluid 407 113 5,453
Comparison of number of N-linked glycosites commonly or uniquely  detected from plasma and tissues/cells Figure 4
Comparison of number of N-linked glycosites commonly or uniquely 
detected from plasma and tissues/cells. Shows the overlap of N-linked 
glycosites identified in plasma with tissues or cells.
295 Plasma 
534
Tissues/Cells
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We also used the number of redundant observations of the
same peptide in the dataset as a crude estimate of the corre-
sponding protein's abundance. Similar to gene expression
profiling, in which the abundance of a particular transcript
can be estimated from the number of observations of a spe-
cific expressed sequence tag (EST) counts [44], the number of
spectra acquired in a specific body fluid, cell type, or tissue
type representing a particular peptide can be used to estimate
the relative protein abundance [45]. A total of 173,841 spectra
were used to identify the N-linked glycosites with Peptide-
Prophet score at least 0.99 in the UniPep database (Table 4).
As expected, we observed a wide range identification fre-
quency assigned to a specific N-linked glycosite in plasma
(from as high as 13,797 spectra assigned to a single N-linked
glycosite to only a single spectrum used to assign a N-linked
glycosite; 104 dynamic range). The highly abundant plasma
proteins generated the N-linked glycosites (MVSHHN#LTT-
GATLINEQWLLTTAK, and NLFLN#HSEN#ATAK) from
haptoglobin and (ADTHDEILEGLNFN#LTEIPEAQIHE-
GFQELLR and YLGN#ATAIFFLPDEGK) from α1-antit-
rypsin, which represented more than 20% of the total
collision-induced dissociation spectra used for positive pep-
tide identification. In contrast to the N-linked glycosites iden-
tified from plasma, cells, and tissues have narrower dynamic
range of protein abundance.
Most cell surface proteins or secreted proteins from cells or
tissues are glycosylated. Therefore, if they are secreted or oth-
erwise released into the bloodstream, then they should be
observable from plasma using selective N-linked glycosite
isolation and MS. Such proteins detected and quantified in
plasma should be highly informative sentinels reporting the
state of the tissue of their origin. We therefore tested the
extent to which N-linked glycosites observed in cells or tis-
sues could also be detected in plasma. The results show that
295 N-linked glycosites are commonly identified from tis-
sues/cells and plasma (Figure 4). This indicates that proteins
from tissues or cells are also detectable in plasma, suggesting
that N-linked glycosite patterns in plasma could potentially
be used to detect the status of tissues in the human body
remotely.
In the present study, we established a database of N-linked
glycosites, an informatics pipeline to populate the database
with data of consistent quality, and generated an initial data-
set of N-linked glycosites covering minimally 3% of the possi-
ble human N-linked glycosites. This database will serve as a
resource for glycobiology. In addition, because the majority of
currently known cancer biomarkers are known to be
glycosylated [46], the database will also significantly contrib-
ute to the development of fast, sensitive, robust, and portable
mass spectrometric assays to identify and quantify candidate
biomarkers [19]. The accurate mass and time tag approach is
such an approach [47] that substantially benefits from a
mapped out proteomic space. Because this and other similar
strategies transform proteomic analyses from a traditional
data-dependant discovery phase into a validation and scoring
phase by directly focusing on biologically relevant peptides/
proteins, they circumvent some of the difficult issues associ-
ated with current methods.
Materials and methods
Materials and reagents
For chromatography procedures, we used high performance
LC grade reagents purchased from Fisher Scientific (Pitts-
burgh, PA, USA). PNGase F was purchased from New Eng-
land Biolabs (Beverly, MA, USA) and hydrazide resin was
from Bio-Rad (Hercules, CA, USA). All other chemicals used
i n  t h i s  s t u d y  w e r e  p u r c h a s e d  f r o m  S i g m a  ( S t .  L o u i s ,  M O ,
USA).
Purification and fractionation of formerly N-linked 
glycosites from plasma
Four datasets were used to generate N-linked glycosites from
plasma and the N-linked glycopeptides were isolated from
plasmausing the method described previously [17]. One set of
data was generated at the Institute for Systems Biology (Seat-
tle, WA, USA) using serum or plasma samples from individu-
als following approval from the Human Subject Institutional
Review Board of the Institute for Systems Biology [29]. The
second set of data was generated at the Institute for Systems
Biology using plasma samples from the HUPO study [30].
The third set of data was generated at the Institute for
Systems Biology from serum purchased from Sigma, and the
forth set of data was generated by the Biological Systems
Analysis and Mass Spectrometry group at Pacific Northwest
National Laboratory (PNNL; Richland, WA, USA) [12].
Purification of glycopeptides from human 
cerebrospinal fluid
The Human Subject Institutional Review Board of the Uni-
versity of Washington approved the study. All 20 partici-
pants, aged 35-45 with a male:female ratio of 1:1, were
compensated community volunteers in good health. Once
written informed consent had been obtained, CSF samples
were collected using a procedure described previously
[48,49].
Glycopeptides were isolated from CSF using the method
developed by Zhang and coworkers [17] with minor modifica-
tions. Briefly, triplicate of 2 ml CSF from pooled CSF samples
was processed through glycopeptide capture procedure, and
the PNGase F released formerly N-linked glycopeptides were
collected and dried down in a speedVac (Thermo Electron
Corporation, Waltham, MA, USA).
Purification and fractionation of formerly N-linked 
glycosylated peptides from cells and tissues
Human tissue specimens were obtained from organs surgi-
cally removed because of cancer under a human subject
approval for prostate and bladder cancer biomarker discoveryR73.10 Genome Biology 2006,     Volume 7, Issue 8, Article R73       Zhang et al. http://genomebiology.com/2006/7/8/R73
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project supported by the Early Detection Research Network
from the National Cancer Institute. Isolation of N-linked glyc-
opeptides from tissues was performed with cell free superna-
tant of collagenase-digested prostate, bladder, and liver
metastasis tissues using a procedure described previously
[17,50].
Isolation of N-linked glycopeptides from cultured SK-BR-3
breast cancer cells used homogenized and fractionated cell
lysates and serum-free culture medium. On reaching conflu-
ence, the SK-BR-3 cells were rinsed five times with serum-
free McCoy's 5a medium to wash out the bovine serum pro-
teins, followed by incubation i n  s e r u m - f r e e  M c C o y ' s  5 a
medium at 37°C for another 24 hours. Then the conditioned
medium fraction was collected and the cells were harvested.
Cells were homogenized in 0.32 mol/l sucrose and 100
mmol/l sodium phosphate buffer (pH 7.5), and separated
into other three fractions via sequential centrifugations (1000
g pellet, 17,000 g pellet, and 17,000 g supernatant). An aliq-
uot of 1 mg protein from each of four fractions was used for N-
linked glycopeptide isolation using the procedure described
previously [17].
Isolation of N-linked glycopeptides from the plasma mem-
branes of lymphocytes was via a modification to the N-linked
glycopeptide capture method for specific labeling of plasma
membrane proteins (unpublished data).
Analysis of peptides by mass spectrometry
Offline fractionated of peptides isolated from plasma samples
by SCX before analysis of each fraction with reverse-phase LC
and MS/MS was described previously [41]. Analysis of pep-
tides from CSF samples using integrated SCX and reverse-
phase C18 columns was done with a previously described pro-
cedure [48,49]. All peptides from other sources were ana-
lyzed by online reverse-phase LC followed by MS/MS without
further fractionation.
Fractionated peptides were analyzed using different mass
spectrometers including LCQ and LTQ mass spectrometers
(Finnigan, San Jose, CA, USA) [7,48,49] and the ESI-qTOF
mass spectrometer (Waters, Milford, MA, USA), in accord-
ance with the manufacturer's instructions [18].
All acquired MS/MS spectra were searched against the IPI
human protein database (version 2.28) using SEQUEST soft-
ware [51] and processed through the pipeline of tools devel-
oped at the Institute for Systems Biology to ensure a
consistent and high-quality set of peptide identifications with
known probability for each peptide sequence assignment. The
database sequence tool was set to the following modifica-
tions: carboxymethylated cysteines, oxidized methionines,
and an enzyme-catalyzed conversion of Asn to Asp at the site
of carbohydrate attachment. No other constraints were
included in the SEQUEST searches.
Database search results were statistically analyzed using
PeptideProphet, which effectively computes a probability for
the likelihood of each identification being correct (on a scale
from 0 to 1) in a data-dependent fashion [39]. A minimum
PeptideProphet probability score filter of 0.5 was used to
remove low probability peptides. The resulted peptide
sequences were processed through UniPep database pipeline
to map individual N-X-S/T sequon containing peptides to
UniPep database (Figure 2).
Subcellular localization of identified proteins
Signal peptides were predicted using SignalP 2.0 [26]. Trans-
membrane regions were predicted using TMHMM (version
2.0) [27]. The TMHMM program predicts protein topology
and the number of transmembrane helices. Information from
SignalP and TMHMM were combined to separate proteins
into the following categories: cell surface (proteins that con-
tained predicted noncleavable signal peptides and no pre-
dicted transmembrane segments); secreted (proteins that
contained predicted cleavable signal peptides and no pre-
dicted transmembrane segments); transmembrane (proteins
that contained predicted transmembrane segments and
extracellular loops and intracellular loops); and intracellular
(proteins that contained neither predicted signal peptides nor
predicted transmembrane regions). All protein sequences
were taken from IPI version 2.28.
UniPep to interrogate proteotypic N-linked 
glycopeptides for proteins in database
UniPep is a web interface that allows researchers to query a
database for a proteotypic N-linked glycopeptide of a specific
protein. UniPep contains all proteins in the IPI database (ver-
sion 2.28) with at least one N-linked glycosylation sequon,
and it allows users to view all of the predicted and identified
N-linked glycopeptides from a specific protein. The scripts
and data were developed within the SBEAMS framework
under the PeptideAtlas branch [29]. For each potential N-
linked glycoprotein, a user can see the protein annotation,
predicted subcellular location, and sequence(s) of predicted
and identified glycopeptide(s). The uniqueness of a peptide in
the database is also presented as number of hits in the data-
base, and for those peptides that are present in multiple pro-
teins, linkage to other proteins in the database is provided.
Any predicted glycopeptides identified experimentally are
listed as an identified peptide with a PeptideProphet score
[39] to allow researcher to evaluate the confidence of the
identification. The sequence of the proteins queried is over-
laid with different sequence features such as the N-linked gly-
cosites, the predicted and identified peptide sequences, signal
peptide, and transmembrane segment(s). This information is
provided to allow the user to choose an identified or predicted
N-linked glycosite for a specific protein of interest.
Data availability
All N-linked glycosites identified from plasma, bladder tis-
sues, breast cancer cells, liver cancer tissues, lymphocytes,http://genomebiology.com/2006/7/8/R73 Genome Biology 2006,     Volume 7, Issue 8, Article R73       Zhang et al. R73.11
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prostate cancer cells, prostate tissues, and CSF in this study
are available from UniPep (Table 3 and 4).
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